Here, we provided evidence that Mettl3 promotes the progression of ovarian, breast and testicle cancers by enhancing the Pfkfb3/lactate/H3K18la/PD-L1 axis, and PLGA-encapsulated Levosimendan synergistically reduces tumor size in combination with CDDP. This evidence concerns the gene METTL3 and neoplasm.